Perspective is developing the next generation of targeted therapies with higher potency payloads and cancer-specific targeting.
Their radiopharmaceutical therapy has the potential to expand the breadth of tumors addressed by RPT.
The company's proprietary chelator and innovative platform are optimized for a broader therapeutic window.
Neuroendocrine Tumors
Phase 1/2a trial results showed anti-tumor activity and tolerability in patients with confirmed PR.
Melanoma Program
PSV359 demonstrated activity against FAP-α expression in metastatic melanoma patients.
Supply Chain Optimization
On-demand order fulfillment ensures regional sites have ready-to-administer products for patients.
- Perspective's approach could revolutionize oncology treatment by targeting tumors more effectively.
- The synergy with immune checkpoint inhibitors provides additional potential for treatment efficacy.
Perspective's radiopharmaceutical platform shows promise in improving cancer treatment outcomes and patient care.